ANI Pharmaceuticals (ANIP) executive reports stock sale and tax trades

Rhea-AI Filing Summary

ANI Pharmaceuticals executive Christopher Mutz, Head of Rare Disease, reported share transactions in company common stock. On February 12, he completed an open-market sale of 7,032 shares at a weighted average price of $76.55 under a Rule 10b5-1 trading plan adopted on June 16, 2025. That same day, 3,173 shares and, on February 14, 2,403 shares were withheld to cover tax liabilities tied to vesting of previously granted restricted stock awards, at prices of $76.70 and $77.36, respectively. Following these transactions, Mutz directly held 90,163 ANI Pharmaceuticals shares.

Insider Trade Summary

Net Seller: 7,032 shares ($538,300)

Net Sell 3 txns

Insider Mutz Christopher

Role HEAD OF RARE DISEASE

Sold 7,032 shs ($538K)

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	2,403	$77.36	$186K
Tax Withholding	Common Stock	3,173	$76.70	$243K
Sale	Common Stock	7,032	$76.55	$538K

Holdings After Transaction: Common Stock — 90,163 shares (Direct)

Footnotes (1)

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025. The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mutz Christopher

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	HEAD OF RARE DISEASE

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		3,173	D	$76.7	99,598	D
Common Stock	02/12/2026		S(2)		7,032	D	$76.55(3)	92,566	D
Common Stock	02/14/2026		F(4)		2,403	D	$77.36	90,163	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 6,202 shares of restricted stock, the grant of which was previously reported on February 18, 2025.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2025.

3. The shares were sold in multiple trades at prices ranging from $75.43 to $76.92. The price reported above reflects the weighted average sales price.

4. Shares withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 4,697 shares of restricted stock, the grant of which was previously reported on February 16, 2024.

Remarks:

	/s/ Christopher Mutz, by attorney-in-fact Meredith W. Cook	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did ANI Pharmaceuticals (ANIP) report for Christopher Mutz?

ANI Pharmaceuticals reported that executive Christopher Mutz disposed of shares through one open-market sale and two tax-withholding transactions. These involved company common stock tied to restricted stock vesting and a pre-established Rule 10b5-1 trading plan.

How many ANI Pharmaceuticals (ANIP) shares did Christopher Mutz sell on the open market?

Christopher Mutz sold 7,032 shares of ANI Pharmaceuticals common stock in an open-market transaction. The filing states this sale used a Rule 10b5-1 trading plan and reported a weighted average price of $76.55 per share across multiple trades.

What were the tax-withholding share dispositions reported by ANI Pharmaceuticals (ANIP)?

The filing shows two tax-withholding dispositions by Christopher Mutz: 3,173 shares at $76.70 and 2,403 shares at $77.36. These covered tax obligations from vesting of restricted stock grants previously reported in 2024 and 2025.

Did Christopher Mutz use a Rule 10b5-1 plan for ANI Pharmaceuticals (ANIP) trades?

Yes. The Form 4 notes that the reported sales were effected under a Rule 10b5-1 trading plan adopted by Christopher Mutz on June 16, 2025. Such plans pre-schedule trades, helping separate them from day-to-day market timing decisions.

How many ANI Pharmaceuticals (ANIP) shares does Christopher Mutz own after these transactions?

After the reported transactions, Christopher Mutz directly owned 90,163 shares of ANI Pharmaceuticals common stock. This figure reflects the open-market sale and the shares withheld to satisfy tax liabilities arising from restricted stock vesting.

What prices were involved in the ANI Pharmaceuticals (ANIP) insider transactions?

The filing lists a weighted average sale price of $76.55 for the 7,032-share open-market sale. Tax-withholding dispositions occurred at $76.70 for 3,173 shares and $77.36 for 2,403 shares, based on market prices at the time.